This makes it possible to speculate that combinatorial therapeutic strategies associating blockers of both PD-1 and TIM-3 could be effective in this tumor in order to antagonize CD8+ T cell exhaustion and suppressive activity. The gene discussed is HAVCR2; the disease is neoplasm.